{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-01-26T16%3A00%3A55.647Z&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Twickenham", "items" : [{"_about" : "http://data.parliament.uk/resources/831118", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/831118/answer", "answerText" : {"_value" : "
The Medicines and Healthcare products Regulatory Agency (MHRA) have received 124 spontaneous reports of suspected adverse drug reactions (ADRs) via the Yellow Card Scheme from prescribers and patients in association with liothyronine in the United Kingdom as of 28 January 2018. The MHRA have not received any spontaneous cases where the reporter has stated their liothyronine is unlicensed.<\/p>
<\/p>
Of the 124 reports, six relate to a brand of liothyronine that is not licensed in the UK. However, it is important to note that patients may have been prescribed a medication while in a foreign country; therefore, a report of a foreign brand cannot be assumed as unlicensed use. Furthermore, while reporters are requested to provide as much detail as possible, detail of the medicinal brand or license is not a compulsory reporting criteria. Therefore, this information is not always provided.<\/p>
<\/p>
Yellow Card data should not be used as an indicator of the frequency of suspected ADRs to medicines. The level of ADR reporting may fluctuate over time due to a variety of reasons such as a medicine being new, stimulated interest/publicity and variations in exposure to the medicine.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2018-01-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-31T14:09:34.423Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Liothyronine"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many reports have been made by prescribers or patients to the Medicines and Healthcare products Regulatory Agency on unlicensed liothyronine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "125126"} , {"_about" : "http://data.parliament.uk/resources/830539", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/830539/answer", "answerText" : {"_value" : "
The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.<\/p>
<\/p>
Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.<\/p>
<\/p>
Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "125070"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T17:14:17.603Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Liothyronine"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the money accrued to the public purse in relation to liothyronine under the (a) the voluntary Pharmaceutical Price Regulation Scheme and (b) the statutory scheme; and when those payments were made.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "125067"} , {"_about" : "http://data.parliament.uk/resources/830540", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/830540/answer", "answerText" : {"_value" : "
The Department has made no assessment. It is for local clinical commissioning groups in conjunction with local providers to make decisions on implementing NHS England\u2019s guidance on liothyronine and, as part of their decision making, to determine the resources available to implement any change.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T17:10:32.493Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Liothyronine"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect on the level of caseloads of consultant endocrinologists as a result of changes to the prescription of liothyronine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "125068"} , {"_about" : "http://data.parliament.uk/resources/830542", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/830542/answer", "answerText" : {"_value" : "
The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.<\/p>
<\/p>
Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.<\/p>
<\/p>
Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "125067"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T17:14:17.65Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Liothyronine"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, whether he plans to reduce the cost of liothyronine by procuring the drug from foreign suppliers; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "125070"} , {"_about" : "http://data.parliament.uk/resources/827954", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/827954/answer", "answerText" : {"_value" : "
The Government has set no specific emissions target for the UK aviation sector in any of the three years named.<\/p>
<\/p>
While domestic aviation is included, emissions from international aviation are currently excluded from the legally-binding 2050 target which was set by the Climate Change Act 2008, and from the five carbon budgets which have been set to date (covering the period up to 2032).<\/p>
<\/p>
However, the UK\u2019s carbon budgets have been set at a level that accounts for international aviation and shipping emissions, so that the UK is on a trajectory that could be consistent with a 2050 target that includes these emissions.<\/p>
<\/p>
Last year the UK was instrumental in reaching a ground-breaking international agreement at the International Civil Aviation Organisation on how to limit the emissions from the sector.<\/p>
<\/p>
The Government will now set out its strategic approach to the aviation sector in a series of consultations leading to the publication of a new Aviation Strategy for the UK in 2019.<\/p>
<\/p>
The Strategy will consider what the best approach and combination of policy measures are at the international and domestic level to ensure we effectively address carbon emissions from aviation.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"} } , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"} , "answeringMemberPrinted" : {"_value" : "Jesse Norman"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T16:55:39.377Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2018-01-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Aviation: Carbon Emissions"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Transport, what targets his Department has set for carbon emissions in the aviation sector in (a) 2030, (b) 2040 and (c) 2050.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "123914"} , {"_about" : "http://data.parliament.uk/resources/827981", "AnsweringBody" : [{"_value" : "Cabinet Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/827981/answer", "answerText" : {"_value" : "
The Prompt Payment Code is monitored by the Prompt Payment Code Compliance Board, under the auspices of the Chartered Institute of Credit Management.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4441", "label" : {"_value" : "Biography information for Oliver Dowden"} } , "answeringMemberConstituency" : {"_value" : "Hertsmere"} , "answeringMemberPrinted" : {"_value" : "Oliver Dowden"} , "dateOfAnswer" : {"_value" : "2018-03-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/827981/answer/previousversion/37128", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4441", "label" : {"_value" : "Biography information for Oliver Dowden"} } , "answeringMemberConstituency" : {"_value" : "Hertsmere"} , "answeringMemberPrinted" : {"_value" : "Oliver Dowden"} } , "questionFirstAnswered" : [{"_value" : "2018-03-14T14:06:58.137Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "53"} , "answeringDeptShortName" : {"_value" : "Cabinet Office"} , "answeringDeptSortName" : {"_value" : "Cabinet Office"} , "date" : {"_value" : "2018-01-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Carillion"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Minister for the Cabinet Office, what assessment he has made of Carillion\u2019s compliance with the Prompt Payment Code.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/207", "label" : {"_value" : "Biography information for Sir Vince Cable"} } , "tablingMemberConstituency" : {"_value" : "Twickenham"} , "tablingMemberPrinted" : [{"_value" : "Sir Vince Cable"} ], "uin" : "123941"} , {"_about" : "http://data.parliament.uk/resources/825829", "AnsweringBody" : [{"_value" : "Cabinet Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/825829/answer", "answerText" : {"_value" : "
Since January 2011, details of central government contracts above the value of £10,000 are published on Contracts Finder. Contracts published prior to 26 February 2015 can be viewed at:<\/p>